{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T10:33:39Z","timestamp":1720607619251},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00108-024-01671-w","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T23:01:46Z","timestamp":1709161306000},"page":"296-307","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostik und Therapie der Virushepatitis\u00a0B und\u00a0D im Jahr 2024","Diagnosis and treatment of viral hepatitis\u00a0B and\u00a0D in 2024"],"prefix":"10.1007","volume":"65","author":[{"given":"Roni","family":"Souleiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"1671_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal\u00a0K, Brunetto\u00a0M, Seto\u00a0WK et\u00a0al (2018) 96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis\u00a0B virus infection. J\u00a0Hepatol 68:672\u2013681. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","journal-title":"J Hepatol"},{"key":"1671_CR2","volume-title":"AASLD:#5009","author":"T Asselah","year":"2023","unstructured":"Asselah\u00a0T, Lampertico\u00a0P, Wedemeyer\u00a0H et\u00a0al (2023) Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta: Primary Endpoint Results from a\u00a0Phase\u00a02b Open-Label, Randomized, Multicenter Study MYR204. In: AASLD:#5009"},{"key":"1671_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra2212151","volume":"389","author":"T Asselah","year":"2023","unstructured":"Asselah\u00a0T, Rizzetto\u00a0M (2023) Hepatitis\u00a0D virus Infection. N\u00a0Engl J Med 389:58\u201370. https:\/\/doi.org\/10.1056\/NEJMra2212151","journal-title":"N Engl J Med"},{"key":"1671_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2021.04.040","volume":"75","author":"T Berg","year":"2021","unstructured":"Berg\u00a0T, Lampertico\u00a0P (2021) The times they are a\u2011changing\u2014a refined proposal for finite HBV nucleos(t)ide analogue therapy. J\u00a0Hepatol 75:474\u2013480. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.040","journal-title":"J Hepatol"},{"key":"1671_CR5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","volume":"78","author":"F van B\u00f6mmel","year":"2023","unstructured":"van B\u00f6mmel\u00a0F, Stein\u00a0K, Heyne\u00a0R et\u00a0al (2023) A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis\u00a0B. J\u00a0Hepatol 78:926\u2013936. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.018","journal-title":"J Hepatol"},{"key":"1671_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg\u00a0M, Lok\u00a0AS\u2011F, Terrault\u00a0NA et\u00a0al (2020) Guidance for design and endpoints of clinical trials in chronic hepatitis\u00a0B\u2014report from the 2019 EASL-AASLD HBV treatment endpoints conference. J\u00a0Hepatol 72:539\u2013557. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.003","journal-title":"J Hepatol"},{"key":"1671_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg\u00a0M, Protzer\u00a0U, Petersen\u00a0J et\u00a0al (2011) Prophylaxis, diagnosis and therapy of hepatitis\u00a0B virus infection\u2014the German guideline. Z\u00a0Gastroenterol 49:871\u2013930. https:\/\/doi.org\/10.1055\/s-0031-1273462","journal-title":"Z Gastroenterol"},{"key":"1671_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U et\u00a0al (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021\u201311). Z\u00a0Gastroenterol 59:691\u2013776. https:\/\/doi.org\/10.1055\/a-1498-2512","journal-title":"Z Gastroenterol"},{"key":"1671_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg\u00a0M, Wong\u00a0VW\u2011S, Locarnini\u00a0S et\u00a0al (2017) The role of quantitative hepatitis\u00a0B surface antigen revisited. J\u00a0Hepatol 66:398\u2013411. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.009","journal-title":"J Hepatol"},{"key":"1671_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","volume":"77","author":"E Degasperi","year":"2022","unstructured":"Degasperi\u00a0E, Anolli\u00a0MP, Uceda Renteria\u00a0SC et\u00a0al (2022) Bulevirtide monotherapy for 48\u00a0weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J\u00a0Hepatol 77:1525\u20131531. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.016","journal-title":"J Hepatol"},{"key":"1671_CR11","doi-asserted-by":"publisher","first-page":"100686","DOI":"10.1016\/j.jhepr.2023.100686","volume":"5","author":"C Dietz-Fricke","year":"2023","unstructured":"Dietz-Fricke\u00a0C, Tacke\u00a0F, Z\u00f6llner\u00a0C et\u00a0al (2023) Treating hepatitis\u00a0D with bulevirtide\u2014real-world experience from 114 patients. JHEP Rep 5:100686. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100686","journal-title":"JHEP Rep"},{"key":"1671_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL 2017 clinical practice guidelines on the management of hepatitis\u00a0B virus infection. J\u00a0Hepatol 67:370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"1671_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","volume":"79","author":"European Association for the Study of the Liver","year":"2023","unstructured":"European Association for the Study of the Liver (2023) EASL clinical practice guidelines on hepatitis delta virus. J\u00a0Hepatol 79:433\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.001","journal-title":"J Hepatol"},{"key":"1671_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"GBD 2019 Hepatitis\u00a0B Collaborators","year":"2022","unstructured":"GBD 2019 Hepatitis\u00a0B Collaborators (2022) Global, regional, and national burden of hepatitis\u00a0B, 1990\u20132019: a\u00a0systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol 7:796\u2013829. https:\/\/doi.org\/10.1016\/S2468-1253(22)00124-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1671_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/jvh.12993","volume":"25","author":"C H\u00f6ner Zu Siederdissen","year":"2018","unstructured":"H\u00f6ner Zu Siederdissen\u00a0C, Maasoumy\u00a0B, Cornberg\u00a0M (2018) New viral biomarkers for hepatitis\u00a0B:\u00a0are we able to change practice? J\u00a0Viral Hepat 25:1226\u20131235. https:\/\/doi.org\/10.1111\/jvh.12993","journal-title":"J Viral Hepat"},{"key":"1671_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","volume":"214","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen\u00a0C, Rinker\u00a0F, Maasoumy\u00a0B et\u00a0al (2016) Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis\u00a0B. J\u00a0Infect Dis 214:1492\u20131497. https:\/\/doi.org\/10.1093\/infdis\/jiw412","journal-title":"J Infect Dis"},{"issue":"23","key":"1671_CR17","doi-asserted-by":"publisher","first-page":"05234","DOI":"10.1016\/j.jhep.2023.10.034","volume":"S0168\u20138278","author":"D H\u00fcppe","year":"2023","unstructured":"H\u00fcppe\u00a0D, Wedemeyer\u00a0H, Cornberg\u00a0M (2023) Population-based screening works: effect of integrating screening for hepatitis\u00a0B and\u00a0C into the general health check-up in Germany. J\u00a0Hepatol S0168\u20138278(23):5234\u20135230. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.034","journal-title":"J Hepatol"},{"key":"1671_CR18","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","volume":"77","author":"P Lampertico","year":"2022","unstructured":"Lampertico\u00a0P, Roulot\u00a0D, Wedemeyer\u00a0H (2022) Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J\u00a0Hepatol 77:1422\u20131430. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.010","journal-title":"J Hepatol"},{"issue":"1","key":"1671_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/apt.16945","volume":"56","author":"M Jachs","year":"2022","unstructured":"Jachs\u00a0M, Schwarz\u00a0C, Panzer\u00a0M et\u00a0al (2022) Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a real world study. Aliment Pharmacol Ther. 56(1):144\u2013154","journal-title":"Aliment Pharmacol Ther."},{"key":"1671_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jhep.2016.02.011","volume":"64","author":"W Li","year":"2016","unstructured":"Li\u00a0W, Urban\u00a0S (2016) Entry of hepatitis\u00a0B and hepatitis\u00a0D virus into hepatocytes: Basic insights and clinical implications. J\u00a0Hepatol 64:32\u2013S40. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.011","journal-title":"J Hepatol"},{"key":"1671_CR21","doi-asserted-by":"publisher","first-page":"667253","DOI":"10.3389\/fpubh.2021.667253","volume":"9","author":"A Maisa","year":"2021","unstructured":"Maisa\u00a0A, Kollan\u00a0C, der Heiden\u00a0AM et\u00a0al (2021) Increasing number of individuals receiving hepatitis\u00a0B nucleos(t)ide analogs therapy in Germany, 2008\u20132019. Front Public Health 9:667253. https:\/\/doi.org\/10.3389\/fpubh.2021.667253","journal-title":"Front Public Health"},{"key":"1671_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker\u00a0F, Zimmer\u00a0CL, H\u00f6ner Zu Siederdissen\u00a0C et\u00a0al (2018) Hepatitis\u00a0B virus-specific T\u00a0cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis\u00a0B. J\u00a0Hepatol 69:584\u2013593. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.004","journal-title":"J Hepatol"},{"key":"1671_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1055\/a-2181-3046","volume":"61","author":"L Sandmann","year":"2023","unstructured":"Sandmann\u00a0L, Berg\u00a0T, Deterding\u00a0K et\u00a0al (2023) Addendum \u201eAntivirale Therapie der chronischen Hepatitis-D-Virusinfektion\u201c zur S3-Leitlinie \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion\u201c der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z\u00a0Gastroenterol 61:1635\u20131653. https:\/\/doi.org\/10.1055\/a-2181-3046","journal-title":"Z Gastroenterol"},{"key":"1671_CR24","unstructured":"Sandmann L, Berg T, Deterding K et\u00a0al (2023) Addendum \u201eAntivirale Therapie der chronischen Hepatitis-D-Virusinfektion\u201c zur S3-Leitlinie \u201eProphylaxe, Diagnostik und. https:\/\/www.dgvs.de\/wp-content\/uploads\/2023\/07\/Addendum-HDV_11.07.23.pdf (Therapie der Hepatitis-B- Virusinfektion\u201c der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS))"},{"key":"1671_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/JEP.S235550","volume":"13","author":"L Sandmann","year":"2021","unstructured":"Sandmann\u00a0L, Cornberg\u00a0M (2021) Experimental drugs for the treatment of hepatitis\u00a0D. J\u00a0Exp Pharmacol 13:461\u2013468. https:\/\/doi.org\/10.2147\/JEP.S235550","journal-title":"J Exp Pharmacol"},{"key":"1671_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale\u00a0AJ, Kreuels\u00a0B, Henrion\u00a0MYR et\u00a0al (2020) The global prevalence of hepatitis\u00a0D virus infection: systematic review and meta-analysis. J\u00a0Hepatol 73:523\u2013532. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008","journal-title":"J Hepatol"},{"key":"1671_CR27","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0168-8278(23)00522-6","volume":"78","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer\u00a0H, Aleman\u00a0S, Brunetto\u00a0M et\u00a0al (2023) Efficacy and safety at 96\u00a0weeks of bulevirtide 2\u202fmg or 10\u202fmg monotherapy for chronic hepatitis\u00a0D:\u00a0results from an interim analysis of a\u00a0phase\u00a03 randomized study. J\u00a0Hepatol 78:S57\u2013S58. https:\/\/doi.org\/10.1016\/S0168-8278(23)00522-6","journal-title":"J Hepatol"},{"key":"1671_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer\u00a0H, Aleman\u00a0S, Brunetto\u00a0MR et\u00a0al (2023) A Phase\u00a03, randomized trial of bulevirtide in chronic hepatitis\u00a0D. N\u00a0Engl J Med 389:22\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2213429","journal-title":"N Engl J Med"},{"key":"1671_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","volume":"23","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer\u00a0H, Sch\u00f6neweis\u00a0K, Bogomolov\u00a0P et\u00a0al (2023) Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis\u00a0B virus and hepatitis\u00a0D virus coinfection (MYR202): a\u00a0multicentre, randomised, parallel-group, open-label, phase\u00a02\u00a0trial. Lancet Infect Dis 23:117\u2013129. https:\/\/doi.org\/10.1016\/S1473-3099(22)00318-8","journal-title":"Lancet Infect Dis"},{"key":"1671_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer\u00a0H, Yurdayd\u00ecn\u00a0C, Dalekos\u00a0GN et\u00a0al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N\u00a0Engl J Med 364:322\u2013331. https:\/\/doi.org\/10.1056\/NEJMoa0912696","journal-title":"N Engl J Med"},{"key":"1671_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","volume":"19","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer\u00a0H, Yurdaydin\u00a0C, Hardtke\u00a0S et\u00a0al (2019) Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis\u00a0D (HIDIT-II): a\u00a0randomised, placebo controlled, phase\u00a02\u00a0trial. Lancet Infect Dis 19:275\u2013286. https:\/\/doi.org\/10.1016\/S1473-3099(18)30663-7","journal-title":"Lancet Infect Dis"},{"key":"1671_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","volume":"77","author":"Z Zhang","year":"2022","unstructured":"Zhang\u00a0Z, Ni\u00a0Y, Lempp\u00a0FA et\u00a0al (2022) Hepatitis\u00a0D virus-induced interferon response and administered interferons control cell division-mediated virus spread. J\u00a0Hepatol 77:957\u2013966. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.023","journal-title":"J Hepatol"},{"key":"1671_CR33","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","volume":"217","author":"CL Zimmer","year":"2018","unstructured":"Zimmer\u00a0CL, Rinker\u00a0F, H\u00f6ner Zu Siederdissen\u00a0C et\u00a0al (2018) Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis\u00a0B is associated with liver damage and HBsAg loss. J\u00a0Infect Dis 217:1656\u20131666. https:\/\/doi.org\/10.1093\/infdis\/jiy097","journal-title":"J Infect Dis"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01671-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01671-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:03:13Z","timestamp":1711105393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01671-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1671"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01671-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"25 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Cornberg gibt an, Honorare f\u00fcr Vortr\u00e4ge und\nBeratung (Advisory Boards) von Gilead (Hersteller\nvon Bulevirtide, Tenofovir); Honorare f\u00fcr Beratung\n(Advisory Boards) von Roche (Hersteller von PEG-IFN,\nHBV-Diagnostik-Assays, Entwicklung neuer Hepatitis\nB-Medikamente) und Honorare f\u00fcr Beratung (Advisory\nBoards) von AiCuris, GSK (Entwicklung neuer Hepatitis\nB-Medikamente) erhalten zu haben. R.\u00a0Souleiman\ngibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}